fullscreen

eFinder

eFinder

Home › Stock Market Impact › Article

Regeneron drops after skin cancer treatment misses late-stage trial goal

Cnbc · · 155 words · By WATCH LIVE
Stock Market Impact Pharmaceutical Trial Results
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Stock Market Impact

Shares of Regeneron fell 11.8% premarket on Monday after the company's experimental treatment missed the main goal in a late-stage trial in patients with advanced melanoma, a type of skin cancer.

Claims checked 7
Techniques found 1
Topics 2

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center75%
Right25%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Shares of Regeneron fell 11.8% premarket on Monday after the company's experimental treatment missed the main goal in a late-stage trial in patients with advanced melanoma, a type of skin cancer.

Why it matters

The drugmaker's fianlimab-cemiplimab combination did not reach statistical significance in improving progression-free survival (PFS), a measure of how long patients live without their advanced melanoma worsening.

Common ground

Advanced melanoma is a serious form of skin cancer that can spread rapidly to other parts of the body, making it harder to treat.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

open_in_new Read the original article: https://www.cnbc.com/2026/05/18/regeneron-drops-after-skin-cancer-treatment-miss…

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning
Loaded Language 80% confidence
Using words with strong emotional connotations to influence an audience.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 7 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

verified Verified 3
check_circle Corroborated 2
verified Verified By Reference 1
info Single Source 1
check_circle
Claim 1: “the company's experimental treatment missed the main goal in a late-stage trial in patients with advanced melanoma”
CORROBORATED
Multiple independent sources confirm that Regeneron's fianlimab combination missed its primary endpoint in a melanoma trial.
travel_explore
web search NEUTRAL — Regeneron’s Fianlimab Misses Primary Endpoint in Melanoma Trial. 18 hours ago. By Jon Napitupulu. Save for later.Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma. Ye…
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…
travel_explore
web search NEUTRAL — The study met its primary endpoint, showing substantially lower rates of grade 3 or 4 treatment-related adverse events at six months in the intratumoral group compared with the intravenous group, 22.6…
https://www.managedhealthcareexecutive.com/view/injecting-im…
travel_explore
web search NEUTRAL — melanoma met its primary endpoint with a statistically significant improvement in PFS observed vs investigator’s choice of therapy.
https://www.linkedin.com/posts/longitude-capital_longitude-p…
verified
Claim 2: “Advanced melanoma is a serious form of skin cancer that can spread rapidly to other parts of the body”
VERIFIED BY REFERENCE
Authoritative medical sources (American Cancer Society, U.S. News) confirm that melanoma is an aggressive skin cancer that can metastasize to other parts of the body.
travel_explore
web search NEUTRAL — Melanoma, a type of skin cancer, is very aggressive. It grows fast and can spread to other parts of the body.Metastasis is when cancer cells spread to other parts of the body. In melanoma, this often …
https://int.livhospital.com/what-is-skin-cancers-manner-of-d…
travel_explore
web search NEUTRAL — Learn the essential facts about skin cancer, including the three main types (basal cell, squamous cell and melanoma), key symptoms, major risk factors and current treatment options like surgery and im…
https://health.usnews.com/conditions/cancer/skin-cancer
travel_explore
web search NEUTRAL — Melanoma skin cancers. Other types of skin cancer. Benign skin tumors.These cancers (especially BCCs) are much less likely to spread (metastasize) to other parts of the body than are melanomas, so the…
https://www.cancer.org/cancer/types/melanoma-skin-cancer/abo…
verified
Claim 3: “The drugmaker's fianlimab-cemiplimab combination did not reach statistical significance in improving progression-free survival (PFS)”
VERIFIED
Regeneron's own update explicitly states that the trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab.
travel_explore
web search NEUTRAL — The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy. No new safety signal…
https://www.barchart.com/story/news/1968125/regeneron-provid…
travel_explore
web search NEUTRAL — If fianlimab plus cemiplimab cannot beat that benchmark against a LAG-3 combination rather than a PD-1 monotherapy, the program’s first-line melanoma ambitions are effectively finished — regardless of…
https://www.clinicaltrialvanguard.com/news/regenerons-fianli…
travel_explore
web search NEUTRAL — An investigational combination of fianlimab, a LAG-3 inhibitor, and cemiplimab (Libtayo; Regeneron Pharmaceuticals, Inc), a PD-1 inhibitor, showed positive data in a phase 1 trial among patients with …
https://www.pharmacytimes.com/view/study-fianlimab-with-cemi…
check_circle
Claim 4: “The study tested fianlimab and Regeneron's approved drug cemiplimab, sold under the brand name Libtayo, as a first-line treatment”
CORROBORATED
Multiple sources confirm the study tested the combination of fianlimab and cemiplimab (Libtayo) as a first-line treatment for advanced melanoma, comparing it against Keytruda.
travel_explore
web search NEUTRAL — The combination of fianlimab and cemiplimab (Libtayo) demonstrated efficacy and safety in patients with advanced melanoma including some who had previously received adjuvant immunotherapy for advanced…
https://www.targetedonc.com/view/fianlimab-plus-cemiplimab-s…
travel_explore
web search NEUTRAL — Regeneron’s anti-Lag3 antibody fianlimab faces a pivotal 2024, with results of its phase 3 study in first-line melanoma, pitting a Libtayo combo against Merck & Co’s Keytruda, due to yield data in the…
https://www.oncologypipeline.com/apexonco/regeneron-works-se…
travel_explore
web search NEUTRAL — Clinical study of fianlimab in combination with cemiplimab in adolescent and adult patients with previously untreated unresectable locally advanced or metastatic melanoma. ClinicalTrials.gov.
https://www.onclive.com/view/fianlimab-plus-cemiplimab-gener…
verified
Claim 5: “The combination treatment showed a numeric improvement of 5.1 months in median PFS when compared with Merck's Keytruda”
VERIFIED
Regeneron's official update explicitly mentions a numeric improvement of 5.1 months in median PFS for the high-dose fianlimab combination compared to pembrolizumab (Keytruda).
travel_explore
web search NEUTRAL — A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab combination compared to pembrolizumab monotherapy.Primary endpoint: median PFS, months (95% Confidence Interv…
https://www.barchart.com/story/news/1968125/regeneron-provid…
travel_explore
web search NEUTRAL — In the combination of fianlimab and cemiplimab, we showed a consistent and reproducible high clinical activity in 3 independent cohorts of patients who were naive to anti–PD-1 in the advanced melanoma…
https://www.targetedonc.com/view/fianlimab-plus-cemiplimab-s…
travel_explore
web search NEUTRAL — Show more results ->. Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations.
https://www.nasdaq.com/press-release/fianlimab-lag-3-inhibit…
verified
Claim 6: “the difference did not reach statistical significance”
VERIFIED
Regeneron's official update confirms that while there was a numeric improvement, the trial 'did not reach statistical significance' for the primary endpoint of PFS.
travel_explore
web search NEUTRAL — The evolution of the modern Western digit for the numeral for five is traced back to the Indian system of numerals, where on some earlier versions, the numeral bore resemblance to variations of the nu…
https://en.wikipedia.org/wiki/5
travel_explore
web search NEUTRAL — Mar 11, 2024 · Curious about some unique facts about the number 5? Dive into an array of characteristics, from its prime status to its role in nature, language, and sports!
https://kidadl.com/facts/math-science/facts-about-the-number…
travel_explore
web search NEUTRAL — Apr 20, 2026 · The number five holds significant symbolic meaning across various cultures and belief systems. It is often seen as representing human life and marriage, stemming from the Pythagorean co…
https://www.britannica.com/science/the-number-five
info
Claim 7: “Shares of Regeneron fell 11.8% premarket on Monday”
SINGLE SOURCE
The provided evidence mentions Regeneron shares falling to $568 in pre-market trading on a Tuesday (BioSpace) and rising 1.4% on a Wednesday (MarketWatch), but none of the sources confirm a specific 11.8% drop on a Monday.
travel_explore
web search NEUTRAL — According to BMO Capital Markets, Regeneron’s earnings missed on top and bottom line. The company reported first quarter earnings of $3 billion.Regeneron’s shares fell to $568 in pre-market trading on…
https://www.biospace.com/business/regeneron-shares-tumble-as…
travel_explore
web search NEUTRAL — Regeneron Pharmaceuticals Inc. shares rose 1.4% in premarket trade Wednesday, after the company beat consensus estimates for the first quarter.
https://www.marketwatch.com/story/regeneron-shares-up-14-pre…
travel_explore
web search NEUTRAL — View pre-market trading, including futures information for the S&P 500, Nasdaq Composite and Dow Jones Industrial Average.
https://www.cnn.com/markets/premarkets
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.